Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NAMPT antisense RNA 1 (*NAMPT-AS1*) is a long non-coding RNA gene transcribed antisense to the *NAMPT* gene locus. Unlike *NAMPT*, which encodes an enzyme critical for NAD+ biosynthesis and implicated in metabolic regulation and disease, *NAMPT-AS1* does not encode a protein and is not classified as a therapeutic target. Its primary annotation is as a lncRNA, a class of molecules generally involved in the post-transcriptional and epigenetic regulation of gene expression. There is currently limited functional or disease-related data specifically on *NAMPT-AS1*. It is important not to confuse *NAMPT-AS1* with *NAMPT* (nicotinamide phosphoribosyltransferase), which is a drug target and is involved in pathways such as cancer metabolism, inflammation, and aging[3][4][7]. Clarification: There is nothing misspelled or inherently incorrect in the provided target information. However, there is often confusion in literature searches between *NAMPT-AS1* (lncRNA) and *NAMPT* (protein/enzyme target)[3]. If you are interested in the enzyme/protein target (NAMPT), properties and drug associations differ substantially.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NAMPT antisense RNA 1 (NAMPT-AS1).